Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines
A. Huber, A. H. Allam, C. Dijkstra, S. Thiem, J. Huynh, A. R. Poh, J. Konecnik, S. P. Jacob, R. Busuttil, Y. Liao, D. Chasinga, W. Shi, M. G. Alorro, S. Forrow, D. V. F. Tauriello, , M. F. Eissmann
This study identifies IL6/STAT3 signaling as a therapeutic target for TP53-mutant gastric cancer by showing its role in metastatic progression driven by mutant Trp53.
bioRxiv · Apr 22, 2024Cancer Biology